English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

    •
    Article
    World of Medicine and Biology / №1(91), 2025 / MODERN APPROACHES TO THE TREATMENT OF PATIENTS WITH A COMBINATION OF ANKYLOSING SPONDYLITIS AND CROHN`S DISEASE
    O. M. Kulchytska, N. V. Kuzminova, S. E. Lozinsky, I. I. Knyazkova, S. O. Kalinichenko, M. S. Nazarova, L. V. Burdeina

    MODERN APPROACHES TO THE TREATMENT OF PATIENTS WITH A COMBINATION OF ANKYLOSING SPONDYLITIS AND CROHN`S DISEASE

    About the author: O. M. Kulchytska, N. V. Kuzminova, S. E. Lozinsky, I. I. Knyazkova, S. O. Kalinichenko, M. S. Nazarova, L. V. Burdeina
    Heading REVIEWS
    Type of article Scentific article
    Annotation Ankylosing spondylitis and Crohn's disease are chronic inflammatory conditions that impact both physical and psychological health. Ankylosing spondylitis primarily affects the spine, causing pain, inflammation, and stiffness, potentially leading to disability. Crohn's disease affects the gastrointestinal tract, causing inflammation, tissue damage, and complications such as stenosis and fistulas, with symptoms like abdominal pain and diarrhea. Although these diseases affect different areas, their inflammatory processes share similar mechanisms and often coexist in the same patient. Both conditions involve immune system dysregulation, leading to chronic systemic inflammation. Treatment aims to reduce symptoms, achieve remission, and prevent complications. However, therapy for comorbid Ankylosing spondylitis and Crohn's disease must be carefully planned, as drugs used for one condition, such as non-steroidal anti-inflammatory drugs for Ankylosing spondylitis, can worsen Crohn's disease. Biological agents targeting inflammatory mechanisms, such as tumor necrosis factor α inhibitors and interleukin blockers, have significantly improved treatment, though individual approaches are necessary due to varying effectiveness and side effects.
    Tags ankylosing spondylitis,inflammatory bowel disease,Crohn's disease,ulcerative colitis
    Bibliography
    • Cardelli C, Monti S, Terenzi R, Carli L. One year in review 2021: Axial spondyloarthritis. Clin. Exp. Rheumatol. 2021; 39: 1272–1281. doi: 10.55563/clinexprheumatol/jlyd1l.
    • Colombel JF, Ungaro RC, Sands BE. Vedolizumab, adalimumab, and methotrexate combination therapy in Crohn’s disease. Clin Gastroenterol Hepatol 2023. doi: 10.1016/j.cgh.2023.09.010.
    • Deodhar A, Sliwinska-Stanczyk P, Xu H. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2021; 80: 1004–13. doi: 10.1136/annrheumdis-2020-219601.
    • Deodhar A, Heijde D, Sieper J. Safety and efficacy of Upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol 2022; 74: 70–80. doi: 10.1002/art.41911.
    • Diaconu A Ceasovschih A, Sorodoc V, Pomirleanu C, Lionte C, Sorodoc L, et al. Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis. Int. J. Mol. Sci. 2022; 23: 11561. doi:  10.3390/ijms231911561.
    • Garcia NM, Cohen NA, Rubin DT. Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022; 10:1121–1128.
    • Geyl S, Guillo L, Laurent V. Transmural healing as a therapeutic goal in Crohn's disease: A systematic review. Lancet Gastroenterol Hepatol. 2021; 6(8):659–667. doi: 10.1016/S2468-1253(21)00096-0.
    • Gordon H, Burisch J, Ellul P. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis 2023; 18:1–37.
    • Gordon H, Minozzi S, Kopylov Y, Verstockt B, Chaparro V,Buskens C,et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. Journal of Crohn's and Colitis, 2024, 18, 1531–1555.
    • Gwinnutt J, Wieczorek M, Balanescu A. 2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases. 2023; 82:48–56. doi:  10.1136/annrheumdis-2021-222020.
    • Hou X, Lee Y, Qian T, Chen C, Tam L. The impact of comorbidities in patients with spondyloarthritis. Int. J. Rheum. Dis. 2023; 26:1222–1224. doi: 10.1111/1756-185X.14682.
    • Iwaszko M, Wielińska J, Świerkot J, Kolossa K, Sokolik R, Bugaj B, et al. IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients. Front. Immunol. 2021; 12:631603. doi: 10.3389/fimmu.2021.631603.
    • Landewé R, Landewe R. The unsustainable bubble of disease-modifying antirheumatic drugs in rheumatology. Lancet Rheumatol 2021; 3:e306–12. doi:10.1016/S2665-9913(21)00013-8.
    • Lindström U, Bengtsson K, Olofsson T. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann Rheum Dis 2021; 80:1445–52. doi:10.1136/annrheumdis-2021-220420.
    • Loza E, Carmona L, Woolf A. Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake. Ann Rheum Dis 2022; 81:1344–7. doi:10.1136/ard-2022-223016.
    • Ma K, Lee Y, Lin C, Shih P, Wei J. Management of extra-articular manifestations in spondyloarthritis. Int. J. Rheum. Dis. 2023; 26:183–186. doi: 10.1111/1756-185X.14485.
    • Martínez-Ramos S, Rafael-Vidal C, Pego-Reigosa J, García S. Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies. Cells. 2022; 11:515. doi: 10.3390/cells11030515.
    • Mishra D, Dhir V, Naidu GSRSNK. Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS study). Rheumatology 2021; 60:1932–41. doi:10.1093/rheumatology/keaa685.
    • Nagy G, Roodenrijs N, Welsing P. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 2022; 81:20–33. doi:10.1136/annrheumdis-2021-220973.
    • Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Annals of the Rheumatic Diseases. 2021; 80:1511–21. doi:10.1136/annrheumdis-2021-221035.
    • Papamichael K, Vande Casteele N, Jeyarajah. Higher postinduction infliximab concentrations are associated with improved clinical outcomes in fistulizing Crohn's disease: An ACCENT-II post hoc analysis. Am J Gastroenterol. 2021; 116(5):1007–14.
    • Parian A, Obi M, Fleshner P, Schwartz D. Management of Perianal Crohn's Disease. The American Journal of Gastroenterology 118(8): p 1323-1331, August 2023. doi: 10.14309/ajg.0000000000002326.
    • Rademacher J, Siderius M, Gellert L, Wink F, Verba M, Maas F, et al. Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy. Semin. Arthritis Rheum. 2022; 53:151974. doi: 10.1016/j.semarthrit.2022.151974.
    • Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. Dis. 2023; 82:19–34. doi: 10.1136/ard-2022-223296.
    • Rueda-Gotor J, López-Mejías R, Remuzgo-Martínez S, Pulito-Cueto V, Corrales A, Lera-Gómez L, et al. Vaspin in atherosclerotic disease and cardiovascular risk in axial spondyloarthritis: A genetic and serological study. Arthritis Res. Ther. 2021; 23:111. doi: 10.1186/s13075-021-02499-7.
    • Sagard J, Olofsson T, Mogard E, Marsal J, Andréasson K, Geijer M, et al. Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis. Arthritis Res. Ther. 2022; 24:42. doi: 10.1186/s13075-022-02733-w.
    • Sagiv M, Adawi M, Awisat A, Shouval A, Peri R, Sabbah F, et al. The association between elevated serum interleukin-22 and the clinical diagnosis of axial spondyloarthritis: A retrospective study. Int. J. Rheum. Dis. 2022; 25:56–60. doi: 10.1111/1756-185X.14246.
    • Sandborn W, Feagan B, Danese S. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies. Inflamm Bowel Dis 2021; 27:994–1007.
    • Walsh J, Magrey M. Clinical Manifestations and Diagnosis of Axial Spondyloarthritis. J. Clin. Rheumatol. 2021; 27:e547–e560. doi: 10.1097/RHU.0000000000001575.
    • Yao J, Zhang M, Wang W. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: A Chinese real-world study. BMC Gastroenterol. 2021; 21(1):380. doi: 10.1186/s12876-021-01946-8.
    • Zhao S, Jones G, Hughes D. Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis. Rheumatology 2021; 60:5734–42. doi:10.1093/rheumatology/keab242.
    • Zhao S, Jones G, Macfarlane G. Association between comorbidities and disease activity in axial spondyloarthritis: results from the BSRBR-AS. Rheumatology 2021; 60:3189–98. doi:10.1093/rheumatology/keaa768.
    Publication of the article «World of Medicine and Biology» №1(91), 2025 year, 238-246 pages, index UDK 616-072.7:616.12-008.331.1:616.12-008.318.4
    DOI 10.26724/2079-8334-2025-1-91-238-246